Which Peptide Synthesis Method Should You Choose?
There is no universal winner between SPPS, LPPS, and hybrid peptide synthesis. Each becomes more or less appropriate depending on the sequence, its purification burden, the target scale, and where the project sits in its development lifecycle. SPPS is evaluated first in many projects across our wholesale research compounds catalog because its resin-bound format allows repeated coupling and washing without isolating an intermediate at every step — an operational property, not proof that it's right for a given peptide. LPPS and hybrid approaches address problems that show up as sequences lengthen or grow more difficult, but each brings its own tradeoffs. What follows works through the variables that actually drive this decision.
Spps Automated Synthesizer Lab
What Is Solid-Phase Peptide Synthesis (SPPS)?
SPPS builds a peptide chain on an insoluble resin, one residue at a time, from the C-terminus toward the N-terminus.
How SPPS works
A protected amino acid couples to the growing chain; excess reagent and soluble byproducts are washed off the resin; the temporary protecting group on the new residue comes off; the cycle repeats until the sequence is complete. The peptide is then cleaved from the resin and the remaining side-chain protecting groups are removed. Because the chain never leaves the resin during assembly, there's no need to isolate an intermediate after every coupling — a wash step does what a full purification would otherwise require, which is why SPPS pairs well with automated synthesizers and parallel synthesis of related sequences.
Where SPPS can become challenging
Reactions confined to a solid support often need a larger reagent excess to reach completion than the equivalent reaction in free solution, and that excess, multiplied across many coupling cycles, drives up solvent use and waste. Each additional cycle is also a chance for something to fall short of completion — small effects individually, but ones that compound across a long or difficult synthesis, so the fraction of chains completing every step correctly can end up well below what a single-step efficiency figure would suggest.
What Is Liquid-Phase Peptide Synthesis (LPPS)?
LPPS, also called solution-phase peptide synthesis, builds the peptide in solution rather than on a solid support.
How LPPS works
Some routes elongate the chain linearly, step by step; others build separate protected fragments and join them later, overlapping conceptually with hybrid synthesis. Intermediates in LPPS are generally isolated rather than staying attached to a support until the end, allowing characterization at each stage.
Where LPPS can become challenging
Whether isolation translates into a practical advantage depends on the specific route. Some solution-phase processes are designed around a smaller reagent excess than the equivalent solid-phase step would need, and certain intermediates, depending on structure, may be amenable to crystallization rather than preparative HPLC. These outcomes aren't inherent to LPPS as a category — they depend on the molecule and how the process was developed around it. What LPPS carries more consistently is the need to isolate and often purify material at each linear step, and as step count grows, yield tends to erode with every additional cycle — a large part of why LPPS today is used mainly for shorter sequences, individual fragments intended for later assembly, and building blocks, rather than a standalone route for long, continuous sequences.
What Is Hybrid Peptide Synthesis?
Hybrid synthesis combines the two approaches rather than replacing either.
Fragment condensation and convergent assembly
The common form uses SPPS to build individual, fully protected fragments, then couples them together, usually in solution — fragment condensation or convergent synthesis. Fragment boundaries matter: a poorly chosen split point can leave a difficult coupling exactly where two fragments meet, so fragment design is part of process development, not an afterthought. Hybrid routes add complexity a continuous synthesis doesn't have — extra purification points, extra analytical checkpoints, and a fragment-coupling step that has to work reliably — which is why hybrid isn't a default even for long peptides. It becomes attractive when a continuous route is expected to accumulate enough inefficiency or purification burden that splitting the sequence is worth the added steps. A related, more specialized technique, native chemical ligation, joins unprotected fragments in solution through a chemoselective reaction; it's generally reserved for very long peptides or small proteins where fragment-based hybrid synthesis reaches its own limits, not a routine fourth option.
Documented examples: enfuvirtide and tirzepatide
Enfuvirtide (Fuzeon), a 36-residue HIV fusion inhibitor, is a documented case of hybrid synthesis at commercial scale. Peer-reviewed accounts describe its large-scale production as built around solid-phase synthesis of protected fragments condensed in solution — engineered to fit this sequence's manufacturing requirements, not evidence that hybrid synthesis is correct for every long peptide.
A more recent example is tirzepatide. A 2021 paper from Eli Lilly's process chemistry group, in Organic Process Research & Development, describes a kilogram-scale GMP process built on a hybrid SPPS/LPPS architecture with continuous manufacturing and real-time analytical monitoring, using nanofiltration for intermediate purification in place of some conventional isolation steps. The published process demonstrates that a hybrid route can be selected when combining solid- and solution-phase operations benefits a specific molecule and scale target — not that this architecture is universally preferable.
SPPS vs. LPPS vs. Hybrid: A Comparison, Not a Length Chart
The table below orients the three approaches by how they operate, not by length — length is one input among several, covered separately below.
| Factor | SPPS | LPPS | Hybrid |
|---|---|---|---|
| Where the peptide/intermediates reside | On a solid resin throughout assembly | Free in solution at each step | Fragments on resin; assembly typically in solution |
| How intermediates are handled | Not isolated between couplings; washed instead | Generally isolated and characterized at each step | Fragments isolated; full sequence assembled from them |
| Where purification occurs | Mostly at the end, on the full crude sequence | Distributed across each linear step | At the fragment level and at final assembly |
| Reagent/solvent considerations | Often needs larger excess and wash solvent per step | Depends on route design | Combines both patterns across fragment synthesis and assembly |
| Automation/process characteristics | Well established for automated synthesizers | Less standardized; varies by route | Fragment synthesis automatable; assembly often manual |
| Where inefficiencies accumulate | Across many cycles in one continuous chain | Across repeated isolation/purification cycles | At fragment boundaries and during coupling |
| Major strategic consideration | Simplicity vs. cumulative loss over a long chain | Purity control vs. step-count burden | Manageability vs. added process complexity |
How Peptide Length Affects the Decision
Length is a real input, but it's not sufficient by itself to predict synthesis difficulty. As a chain grows, there are more coupling and deprotection cycles across which small inefficiencies can accumulate — genuine pressure toward fragment-based strategies for longer sequences. But a length threshold applied on its own will misclassify plenty of real sequences: composition can be a major determinant of synthesis difficulty, and length alone is an incomplete predictor, since a moderate-length peptide with a difficult internal region can be harder to produce cleanly than a considerably longer peptide without one.
How Sequence Complexity and Aggregation Change the Calculus
As a chain elongates on the resin, neighboring chains can begin associating with each other, including through beta-sheet-like hydrogen bonding, rather than staying independently accessible to incoming reagents. This reduces reagent access, contributes to incomplete coupling, and often produces truncated or deleted sequences that further coupling cycles don't fully correct.
Certain patterns are disproportionately associated with this behavior: stretches of hydrophobic residues, repeated or clustered proline residues, and regions prone to ordered secondary structure while attached to the resin. A sequence with one of these patterns can be genuinely harder to synthesize than a longer sequence without them — the practical reason to evaluate composition specifically rather than treating length as a proxy for difficulty.
How Modifications Affect Synthesis Strategy
Cyclization — a disulfide bond, a lactam bridge, or another linkage — has to be scheduled somewhere in the process, and whether it happens on-resin or after cleavage can influence which approach fits better. Non-natural or sterically demanding amino acids can be difficult to couple regardless of method, since the difficulty is often local to that residue rather than the whole sequence. Multiple simultaneous modifications tend to compound these considerations rather than average out.
Hybrid Peptide Synthesis Purification
How Fmoc and Boc Chemistry Fit Into the Decision
Fmoc and Boc are the two dominant temporary protecting-group strategies controlling which end of the growing chain reacts during each coupling cycle, relevant to SPPS and to fragment preparation for hybrid routes. The choice affects deprotection conditions throughout synthesis and which side-chain protecting groups and cleavage chemistries are compatible with the route. For sequences with acid-sensitive modifications, or fragments needing a particular deprotection profile for a planned hybrid assembly, protecting-group strategy becomes a genuine input into route design — worth reviewing alongside strict laboratory compliance standards early with whoever is developing the process.
Purification and Analytical Considerations
A route's feasibility and economics can't be judged from the synthesis step alone. A crude SPPS product typically contains the target sequence mixed with truncated and deleted byproducts, and separating those out is often the most resource-intensive part of the process. LPPS and fragment-based hybrid routes distribute some of that burden earlier, since intermediates are checked along the way — surfacing problems sooner, though adding workload per stage. Confirming identity, purity, and byproduct absence through rigorous analytical verification and Certificates of Analysis (COA) needs to be planned in from the start, not treated as a final checkpoint.
What Drives Peptide Synthesis Cost?
Cost is shaped by a combination of factors rather than a single number scaling cleanly with length. Building-block consumption tracks sequence length and the reagent excess a step requires. Solvent and resin use add up across the coupling and deprotection cycles a route needs. Isolating intermediates — in a linear LPPS route, or between hybrid fragments — adds labor, equipment time, and analytical testing per stage. Purification is frequently the largest single cost driver, often exceeding the raw materials feeding the coupling chemistry itself. Yield and scale interact with all of this: a route efficient at small scale can behave differently once volumes and purification loads increase. Waste, often discussed as process mass intensity, tracks closely with solvent and reagent use. Synthesis strategy doesn't eliminate these cost drivers; it shifts how much falls into each category.
Scaling from Research to Larger-Scale Production
A route that performs well at milligram, research-use scale doesn't automatically behave the same way once volumes increase. Solvent and reagent quantities that are a minor consideration at small scale become significant drivers of cost and waste as production grows. Mixing and mass-transfer behavior can also shift at larger scale, which is one reason sequences that behave well in the lab sometimes reveal aggregation or coupling problems only after scale-up begins. This is generally why scale-up gets treated as its own phase of process development in custom peptide manufacturing services rather than a straightforward multiplication of a small-scale recipe — no single strategy is guaranteed to scale more favorably than another. The tirzepatide process described earlier illustrates a hybrid, continuous-manufacturing approach engineered around a defined scale and quality target, not evidence that this architecture generalizes automatically to other molecules.
How Development Stage Influences the Decision
Priorities for a given peptide can shift across a project's lifecycle even when the sequence itself doesn't change. Early on, generating material quickly and staying flexible often matter more than optimizing every step, which is part of why SPPS's compatibility with rapid, automated iteration sees heavy use at this stage. As a program moves toward larger, more consistent production, reproducibility, impurity control, and process economics carry more weight relative to raw speed. Development stage is a meaningful input, but it doesn't override sequence-specific factors — a difficult, aggregation-prone sequence can require a fragment-based approach even early on, and a straightforward sequence may stay on one continuous method well into later development. B2B buyers establishing ongoing procurement channels can configure volume specifications through a dedicated wholesale application portal.
A Practical Decision Framework
No algorithm can select a synthesis strategy automatically — but working through the same set of factors for any given project produces a far more grounded decision than defaulting to habit. The table below is meant to structure that evaluation, not to score it.
| Factor | What to examine | How it can influence the strategy |
|---|---|---|
| Sequence length | Total residue count and cumulative cycle count for a continuous route | Longer sequences increase pressure toward fragment-based approaches, but only in combination with other factors below |
| Sequence composition | Hydrophobic stretches, proline clusters, structure-forming regions | Difficult composition can justify a fragment split even in a moderate-length sequence |
| Aggregation risk | Whether the sequence resembles known aggregation-prone patterns | May prompt resin or condition changes, or a decision to isolate segments earlier |
| Difficult couplings | Specific residues or junctions known to be sterically or chemically demanding | Can determine where a fragment boundary should sit, regardless of overall method |
| Modifications | Cyclization, non-natural residues, other structural features | Determines when in the process a modification is introduced and which protecting-group strategy fits |
| Protecting-group strategy | Fmoc vs. Boc compatibility with planned modifications and cleavage chemistry | Shapes which fragments or routes are chemically feasible |
| Purification requirements | Expected complexity of the crude mixture | Argues for isolating intermediates earlier when the crude mixture is likely to be difficult to resolve at the end |
| Desired scale | Research-scale batch vs. larger production target | Larger scale raises the relative importance of solvent, reagent, and purification economics |
| Development stage | Current priority: speed and iteration, or robustness and reproducibility | Early-stage flexibility can favor continuous SPPS even where a later-stage process would be redesigned |
| Robustness/reproducibility | Whether the peptide needs to be made reliably across many batches | Repeated, high-reliability production tends to favor routes with earlier, more distributed quality checks |
| Resource/process efficiency | Reagent, solvent, labor, and purification load taken together | Identifies which approach uses resources most efficiently for this specific project, not in the abstract |
These factors interact rather than stack independently. A sequence short enough to suggest LPPS on length alone might contain a difficult coupling favoring solid-phase conditions instead. A long sequence with well-behaved composition might stay manageable on continuous SPPS, while a shorter but aggregation-prone sequence might justify the added complexity of a hybrid route despite its length. Working through the table above for a specific project, rather than anchoring on any single row, is what leads to a workable choice — and it's worth having that conversation directly with whoever will develop the process, since sequence-specific behavior often can't be fully predicted beforehand.
Sources / Further Reading
- Frederick, M.O. et al., "Kilogram-Scale GMP Manufacture of Tirzepatide Using a Hybrid SPPS/LPPS Approach with Continuous Manufacturing," Organic Process Research & Development 2021, 25(7), 1628–1636.
- Bray, B.L., "Large-scale manufacture of peptide therapeutics by chemical synthesis," Nature Reviews Drug Discovery.
- Beilstein Journal of Organic Chemistry review on automated solid-phase peptide synthesis, convergent/fragment-condensation production of therapeutic peptides, and enfuvirtide manufacturing.
- PubMed, "Optimized sample preparation for MALDI mass spectrometry analysis of protected synthetic peptides," on enfuvirtide's convergent solid-/solution-phase manufacturing strategy.
- PMC, "Development of ArgTag for Scalable Solid-Phase Synthesis of Aggregating Peptides," on resin-bound chain aggregation.
- PNAS, "Proximity-driven acceleration of challenging solid-phase peptide couplings," on aggregation and coupling efficiency in SPPS.
- American Chemical Society, "Next-Generation Peptide Manufacturing: Green Chemistry and Sustainable Development via LPPS, Continuous-Flow, and Integrated Platforms," on process mass intensity and sustainability considerations in peptide manufacturing.
